HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Papers In Press, published online ahead of print December 1, 2004
J. Lipid Res., doi:10.1194/jlr.M400213-JLR200

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: M400213-JLR200v1 45/12/2260    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teiber, J. F. Articles by La Du, B. N. Search for Related Content PubMed PubMed Citation Articles by Teiber, J. F. Articles by La Du, B. N. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 45, 2260-2268, December 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH

John F. Teiber, Dragomir I. Draganov and Bert N. La Du¹

Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI

¹ To whom correspondence should be addressed. e-mail: bladu{at}umich.edu

Purified serum paraoxonase (PON1) had been shown to attenuate the oxidation of LDL in vitro. We critically reevaluated the antioxidant properties of serum PON1 in the in vitro assays initiated with copper or the free radical generator 2,2'-azobis-2-amidinopropane hydrochloride (AAPH). The antioxidant activity of different purified PON1 preparations did not correlate with their arylesterase (AE), lactonase, or phospholipase A₂ activities or with the amounts of detergent or protein. Dialysis of three of these preparations resulted in a 30–40% loss of their AE activities but in a complete loss of their antioxidant activities. We also followed the distribution of the antioxidant activity during human serum PON1 purification by two purification methods. The antioxidant activity of the anion-exchange chromatography fractions did not copurify with PON1 using either method and could largely be accounted for by the "antioxidant" activity of the detergent present.

In conclusion, using the copper or AAPH in vitro assays, no PON1-mediated antioxidant activity was detected, suggesting that the removal of PON1 from its natural environment may impair its antioxidative activity and that this assay with highly purified PON1 may be an inappropriate method with which to study the antioxidative properties of the enzyme.

Abbreviations: AAPH, 2,2'-azobis-2-amidinopropane hydrochloride; AE, arylesterase; DDM, n-dodecyl-ß-D-maltoside; DLPC, L--dilauroylphosphatidylcholine; PLA₂, phospholipase A₂; PON1, paraoxonase; TBARS, thiobarbituric acid-reactive substances

Supplementary key words paraoxonase 1 • oxidized low density lipoprotein • antioxidants • atherosclerosis • 2,2'-azobis-2-amidinopropane hydrochloride

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Jaichander, K. Selvarajan, M. Garelnabi, and S. Parthasarathy Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin J. Lipid Res., October 1, 2008; 49(10): 2142 - 2148. [Abstract] [Full Text] [PDF]

				T. Kriska, G. K. Marathe, J. C. Schmidt, T. M. McIntyre, and A. W. Girotti Phospholipase Action of Platelet-activating Factor Acetylhydrolase, but Not Paraoxonase-1, on Long Fatty Acyl Chain Phospholipid Hydroperoxides J. Biol. Chem., January 5, 2007; 282(1): 100 - 108. [Abstract] [Full Text] [PDF]

				L. Gaidukov, M. Rosenblat, M. Aviram, and D. S. Tawfik The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux J. Lipid Res., November 1, 2006; 47(11): 2492 - 2502. [Abstract] [Full Text] [PDF]

				A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]

				C. S. Carlson, P. J. Heagerty, T. S. Hatsukami, R. J. Richter, J. Ranchalis, J. Lewis, T. J. Bacus, L. A. McKinstry, G. D. Schellenberg, M. Rieder, et al. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease J. Lipid Res., May 1, 2006; 47(5): 1014 - 1024. [Abstract] [Full Text] [PDF]

				M. Rosenblat, L. Gaidukov, O. Khersonsky, J. Vaya, R. Oren, D. S. Tawfik, and M. Aviram The Catalytic Histidine Dyad of High Density Lipoprotein-associated Serum Paraoxonase-1 (PON1) Is Essential for PON1-mediated Inhibition of Low Density Lipoprotein Oxidation and Stimulation of Macrophage Cholesterol Efflux J. Biol. Chem., March 17, 2006; 281(11): 7657 - 7665. [Abstract] [Full Text] [PDF]

				D. I. Draganov, J. F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B. N. La Du Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities J. Lipid Res., June 1, 2005; 46(6): 1239 - 1247. [Abstract] [Full Text] [PDF]

				A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J. Lipid Res., March 1, 2005; 46(3): 389 - 403. [Abstract] [Full Text] [PDF]